(Press-News.org) MIAMI, FL – OCTOBER 25, 2012 – Patients who receive a drug-eluting stent (DES) and demonstrate low levels of platelet inhibition are more likely to have blood clots form on the stent and suffer a possible heart attack; conversely, patients with higher levels of platelet inhibition are at greater risk for bleeding complications. One-year results of the ADAPT-DES study were presented today at the 24th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium. Sponsored by the Cardiovascular Research Foundation, TCT is the world's premier educational meeting specializing in interventional cardiovascular medicine.
At last year's TCT meeting, ADAPT-DES researchers demonstrated a strong relationship between platelet hyporesponsiveness to clopidogrel and subsequent stent thrombosis (clot formation) up to 30 days after stent implantation. Now after one year of follow up, the ADAPT-DES team is reporting the overall treatment implications of platelet hyporesponsiveness on patient outcomes.
In this large multicenter registry, 8,583 patients undergoing a percutaneous coronary intervention (PCI) with at least one drug-eluting stent were enrolled at 11 sites between January 2008 and September 2010. Researchers assessed platelet reactivity with the VerifyNow Aspirin, P2Y12, and IIb/IIIa tests. Patients were followed for one year to determine the relationship between platelet hyporesponsiveness and subsequent events. At one year, stent thrombosis occurred in 70 patients (0.84 percent), heart attack in 224 (2.7 percent), major bleeding in 531 (6.2 percent), and death in 161 (1.9 percent).
The number of platelet reactivity units (PRU) was measured by the VerifyNow P2Y12 test. Clopidogrel hyporesponsiveness was defined by a PRU of greater than 208 and was present in 42.7 percent of patients. Clopidogrel hyporesponsiveness was significantly associated with stent thrombosis (1.3 percent vs. 0.5 percent) and heart attack (3.9 percent vs. 2.7 percent), but was also found to protective against major bleeding (5.6 percent vs. 6.7 percent). Clopidogrel hyporesponsiveness was also associated with one-year mortality (2.4 percent vs. 1.5 percent). However, because clopidogrel hyporesponsiveness is also associated with other patient risk factors and baseline characteristics, multivariable modeling was also performed, which demonstrated no independent association between clopidogrel hyporesponsiveness and mortality.
"Results from the ADAPT-DES registry suggest that clopidogrel hyporesponsiveness after implantation of a drug-eluting stent is an independent predictor of one-year stent thrombosis and heart attack, but it is also protective against major bleeding, both of which impact mortality," said lead investigator Gregg W. Stone, MD. Dr Stone is Professor of Medicine at Columbia University College of Physicians and Surgeons and Director of Cardiovascular Research and Education at the Center for Interventional Vascular Therapy at NewYork-Presbyterian Hospital/Columbia University Medical Center.
"Clopidogrel hyporesponsiveness was not found to be an independent predictor of one-year mortality. Therefore, overcoming clopidogrel hyporesponsiveness with more potent antiplatelet agents is unlikely to improve survival unless the beneficial effect of reducing stent thrombosis and heart attack can be separated from the likely increase in bleeding that results from greater platelet inhibition," said Dr. Stone.
Dr. Stone also added: "Hyporesponsiveness to aspirin was unrelated to stent thrombosis, heart attack or death, but may be related to bleeding. This questions the utility of aspirin in patients treated with drug-eluting stents."
###The results of the ADAPT-DES One Year study will be presented on Thursday, October 25 at 12:15 PM EST in the Main Arena (Hall D) of the Miami Beach Convention Center.
The ADAPT-DES trial was sponsored by the Cardiovascular Research Foundation with research support from Boston Scientific, Abbott Vascular, Medtronic, Cordis, Biosensors, The Medicines Company, Daiichi Sankyo, Eli Lilly, Volcano, and Accumetrics. Dr. Stone reported consulting fees from Abbott Vascular, Boston Scientific, Medtronic, The Medicines Company, Daiichi Sankyo, Eli Lilly, Astra Zeneca and Volcano.
About CRF
The Cardiovascular Research Foundation (CRF) is an independent, academically focused nonprofit organization dedicated to improving the survival and quality of life for people with cardiovascular disease through research and education. Since its inception in 1991, CRF has played a major role in realizing dramatic improvements in the lives of countless numbers of patients by establishing the safe use of new technologies and therapies in interventional cardiovascular medicine.
Transcatheter Cardiovascular Therapeutics (TCT) is the annual scientific symposium of the Cardiovascular Research Foundation. TCT gathers leading medical researchers and clinicians from around the world to present and discuss the latest developments in the field.
For more information, visit www.crf.org.
If an object slams into the glass façade of a high-rise building, the glass must not shatter and fall down, because it could harm pedestrians below. In addition, the window panes must hold if a person were to fall against it from the inside. Architects and builders therefore must use something stronger than laminated safety glass on the façades of high rise buildings. The same applies to the windshields on cars. Safety glass prevents passengers in an accident from getting hurt by glass shards. And shop windows made of safety glass are expected to reliably safeguard the ...
One man's death is a tragedy; a million is a statistic. - Joseph Stalin
This book of prose poems is a captivating visit to the legendary town of Spoon River, viewed through the epitaphs of its residents. SPOON RIVER REVISITED is an insightful sequel to Edgar Lee Master's 1916 classic, Spoon River Anthology. The people who share their modern stories still struggle with challenges of growing up, making their way through life, and passing on.
Death has an undeserved, bad reputation! Within the understandings of western medicine, when the body stops working, that is ...
MINNEAPOLIS – A new study suggests that women who begin taking hormone therapy within five years of menopause may reduce their risk of developing Alzheimer's disease. The research is published in the October 24, 2012, online issue of Neurology®, the medical journal of the American Academy of Neurology.
"This has been an area of debate because observational studies have shown a reduced risk of Alzheimer's disease with hormone therapy use, while a randomized controlled trial showed an increased risk. Our results suggest that there may be a critical window near menopause ...
MAYWOOD, Ill. - Nearly 80 million Americans would no longer need to take vitamin D supplements under new Institute of Medicine guidelines, according to a study by Loyola University Chicago Stritch School of Medicine researchers.
Results were published Oct. 24, 2012 in the journal PLOS ONE.
The new guidelines advise that almost all people get sufficient vitamin D when their blood levels are at or above 20 nanograms per milliliter (ng/ml). Older guidelines said people needed vitamin D levels above 30 ng/ml.
Holly Kramer, MD, MPH and colleagues examined data from 15,099 ...
HOUSTON -- (October 24, 2012) – , said a Baylor College of Medicine physician-scientist who was part of the local team that took part in the international effort. A report appears online in the journal Nature.
"We now know every gene involved in pancreatic cancer," said Dr. William Fisher, professor of surgery and director of the Elkins Pancreas Center at BCM. "This study ushers in a whole new era of taking care of patients with pancreatic cancer. We will look back on this as a turning point in understanding and treating this disease."
The study follows a five-year ...
BOSTON––Findings from a nationwide study led by researchers at Dana-Farber Cancer Institute suggest that patients with advanced lung or colorectal cancer are frequently mistaken in their beliefs that chemotherapy can cure their disease.
The study, published in the Oct. 25 issue of the New England Journal of Medicine, found that 69 percent of patients with advanced lung cancer and 81 percent of patients with advanced colorectal cancer did not understand that the chemotherapy they were receiving was not at all likely to cure their disease. Their expectations run counter ...
Residents living in high-income white and high-income integrated neighborhoods were more likely to receive bystander CPR (cardiopulmonary resuscitation) during an out-of-hospital cardiac arrest than arrest victims in low-income black neighborhoods, according to a publication in the Oct. 25 issue of the New England Journal of Medicine (NEJM). Arrest victims in low-income white, low-income integrated and high-income black neighborhoods were also less likely to receive bystander CPR.
In an effort to look at future CPR training processes and public health planning, researchers ...
In an editorial appearing in the October 25 issue of The New England Journal of Medicine, medical oncologists at Johns Hopkins and Brigham and Women's hospitals provide a four-point plan for integrating palliative care discussions throughout the treatment of patients with terminal illnesses. They write that better planning and communication may improve symptoms, stress, and survival time, as well as lower health care costs at the end of life.
The two physicians suggest that their colleagues should discuss palliative care with patients during initial talks about prognosis ...
European countries with gaps in border security surrounding agricultural imports have been invaded by the largest number of exotic insect pests, according to research published Oct 24 in the open access journal PLOS ONE by Steven Bacon and colleagues from the Swiss Federal Research Station Agroscope ART and the University of Fribourg, Switzerland.
Invasive agricultural pests pose growing environmental and economic problems, threatening biodiversity and costing billions of dollars in economic losses annually. Large volumes of cross-border trade increase the risks of invasion, ...
PORTLAND, Ore. - Oregon Health & Science University's development of a new gene therapy method to prevent certain inherited diseases has reached a significant milestone. Researchers at the university's Oregon National Primate Research Center and the OHSU Department of Obstetrics & Gynecology have successfully demonstrated their procedure in human cells. It's believed that this research, along with other efforts, will pave the way for future clinical trials in human subjects.
The research results are online Wednesday, Oct. 24, in the highly respected journal Nature. Dr. ...
